BR112022015994A2 - MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS - Google Patents

MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS

Info

Publication number
BR112022015994A2
BR112022015994A2 BR112022015994A BR112022015994A BR112022015994A2 BR 112022015994 A2 BR112022015994 A2 BR 112022015994A2 BR 112022015994 A BR112022015994 A BR 112022015994A BR 112022015994 A BR112022015994 A BR 112022015994A BR 112022015994 A2 BR112022015994 A2 BR 112022015994A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
immunizing
multivalent immunogenic
dirophilariosis
inducing
Prior art date
Application number
BR112022015994A
Other languages
Portuguese (pt)
Inventor
Kalyanasundaram Ramaswamy
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/790,277 external-priority patent/US11370814B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BR112022015994A2 publication Critical patent/BR112022015994A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO IMUNOGÊNICA MULTIVALENTE, VETOR RECOMBINANTE, CÉLULA HOSPEDEIRA RECOMBINANTE, E, MÉTODOS PARA INDUZIR UMA RESPOSTA IMUNE PROTETORA E PARA IMUNIZAR UM ANIMAL CONTRA DIROFILARIOSE. A presente invenção é uma composição imunogênica multivalente para imunizar um animal contra filariose. Em algumas modalidades, os antígenos da composição imunogênica multivalente são baseados em proteína, baseados em DNA ou uma combinação dos mesmos. Esta invenção também provê um método e kit para detectar um nematódeo filarial e determinar a eficácia da vacina.MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS. The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

BR112022015994A 2020-02-13 2021-02-12 MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS BR112022015994A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/790,277 US11370814B2 (en) 2010-11-15 2020-02-13 Vaccine and methods for detecting and preventing filariasis
PCT/US2021/017813 WO2021163448A2 (en) 2020-02-13 2021-02-12 Vaccine and methods for detecting and preventing filariasis

Publications (1)

Publication Number Publication Date
BR112022015994A2 true BR112022015994A2 (en) 2022-10-11

Family

ID=77295222

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015994A BR112022015994A2 (en) 2020-02-13 2021-02-12 MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS

Country Status (7)

Country Link
EP (1) EP4103225A2 (en)
JP (1) JP2023513607A (en)
CN (1) CN115209916A (en)
AU (1) AU2021218797A1 (en)
BR (1) BR112022015994A2 (en)
CA (1) CA3167346A1 (en)
WO (1) WO2021163448A2 (en)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5207987A (en) 1990-05-21 1993-05-04 Pb Diagnostic Systems Inc. Temperature controlled chamber for diagnostic analyzer
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5639876A (en) * 1991-02-12 1997-06-17 Heska Corporation Nucleic acid molecules encoding novel parasitic helminth proteins
JP2844264B2 (en) 1992-07-01 1999-01-06 ベーリング ダイアグノスティックス，インコーポレーテッド Automated analytical instrument with fluid sample holding tray transfer assembly
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5910287A (en) 1997-06-03 1999-06-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for fluorescence measurements of biological and biochemical samples
US6229603B1 (en) 1997-06-02 2001-05-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for spectroscopic measurements
US6063338A (en) 1997-06-02 2000-05-16 Aurora Biosciences Corporation Low background multi-well plates and platforms for spectroscopic measurements
US6426050B1 (en) 1997-05-16 2002-07-30 Aurora Biosciences Corporation Multi-well platforms, caddies, lids and combinations thereof
US6150135A (en) * 1997-05-23 2000-11-21 Heska Corporation Dirofilaria and brugia thioredoxin peroxidase type-2 (TPX-2) nucleic acid molecules, and uses thereof
US6814933B2 (en) 2000-09-19 2004-11-09 Aurora Biosciences Corporation Multiwell scanner and scanning method
US6448089B1 (en) 1999-10-12 2002-09-10 Aurora Biosciences Corporation Multiwell scanner and scanning method
US7459314B2 (en) 2003-02-13 2008-12-02 Inverness Medical Switzerland Gmbh Lateral flow immunoassay controls
CN101031798B (en) 2004-07-29 2012-06-27 瑞莱诊断体系有限公司 Quantitative lateral flow system and assay
US20060051348A1 (en) 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US7387890B2 (en) 2004-12-16 2008-06-17 Chembio Diagnostic Systems, Inc. Immunoassay devices and use thereof
US7939342B2 (en) 2005-03-30 2011-05-10 Kimberly-Clark Worldwide, Inc. Diagnostic test kits employing an internal calibration system
US7976795B2 (en) 2006-01-19 2011-07-12 Rheonix, Inc. Microfluidic systems
US20100129935A1 (en) 2008-11-25 2010-05-27 Sarah Daniel Maddison Pregnancy testing method
US20100196200A1 (en) 2009-02-05 2010-08-05 Jin Po Lee Biological test strip
CN110051832B (en) * 2019-05-31 2020-11-10 四川农业大学 Heartworm disease vaccine

Also Published As

Publication number Publication date
WO2021163448A2 (en) 2021-08-19
JP2023513607A (en) 2023-03-31
AU2021218797A1 (en) 2022-08-25
CA3167346A1 (en) 2021-08-19
CN115209916A (en) 2022-10-18
WO2021163448A3 (en) 2021-11-25
EP4103225A2 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
BR112022014808A2 (en) COMPOSITIONS AND METHODS FOR VACCINES TO PREVENT AND TREAT CORONAVIRUS-SARS-COV-2 INFECTION
CL2021000636A1 (en) African swine fever virus vaccine
BR112023005961A2 (en) MODIFIED NUCLEIC ACID MOLECULE, COMBINED VACCINE, NANOPARTICLE, MRNA NANOCLUSTER, METHOD FOR PREVENTING OR TREATING A CORONAVIRUS INFECTION, METHOD FOR BOOSTING AN ADAPTIVE IMMUNE RESPONSE, IMMUNOGENIC PEPTIDE AND IMMUNOGENIC COMPOSITION
BRPI0909123B8 (en) monoclonal antibodies, expression vector, host cell, pharmaceutical composition, use of said antibody, diagnostic kit and assay methods to detect the presence of influenza a virus epitopes
BR112018001572A2 (en) method for inducing an immune response, antigen, adenovirus, use of antigen and adenovirus, and polynucleotide.
BR112017012852A2 (en) new tilapia virus and uses of it
BRPI0518146A (en) parts kit, use of a recombinant defective adenovirus in replication, and method of vaccinating a mammal for malaria infection
BR112018017307A2 (en) isolated nucleic acid molecule, composition, and methods for inducing an immune response against a Zika virus, for treating an individual, and for preventing a Zika virus infection
BR112017012484A2 (en) isolated virus, cell culture, gene encoding a protein, protein, DNA fragment, living recombinant vector virus, pseudo particle, vaccine, antibody or antiserum, method for preparing a vaccine, and, diagnostic test kit.
BR112022013236A2 (en) ANTI-CD73 ANTIBODIES AND USES THEREOF
BR112019010275A2 (en) recombinant adenovirus, composition, use of adenovirus or composition, method of inducing an immune response in a patient, and non-human simian adenovirus
BR112015002131A8 (en) RECOMBINANT VACCINIA ANKARA VIRUS (MVA), PHARMACEUTICAL COMPOSITION AND USE OF SUCH RECOMBINANT MVA
EA201990718A1 (en) VECTORS OF Adenovirus of dogs
BRPI0906997A2 (en) Protein, use of the combining protein or fragment thereof, method for inducing an immune response in an individual, method for treating a pacemaker, nicleic acid construction, host cell ezpression vector, vaccine, antibody, and, pharmaceutical composition
BR112012031211A2 (en) methods and vaccine to reduce campylobacter infection
BRPI1007721B1 (en) vaccine composition for use in inducing an immune response against a rotavirus in an individual, a rotavirus strain isolated from cdc-9 and a rotavirus strain isolated from cdc-66
BR112018008840A2 (en) single domain antibodies directed against intracellular antigens
BR112022011885A2 (en) NUCLEIC ACID MOLECULE, IMMUNOGENIC COMPOSITION, PEPTIDE, AND, METHODS TO INDUCE AN IMMUNE RESPONSE AND TO TREAT OR PREVENT A PATHOLOGY
BR112017026649A2 (en) recombinant modified vaccinia ankara (mva) foot-and-mouth virus (fmdv) vaccine
BR112022015994A2 (en) MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS
BR112022026580A2 (en) COMPOSITIONS AND METHODS TO INDUCE AN IMMUNE RESPONSE AGAINST CORONAVIRUS
CO2023014970A2 (en) Coronavirus vaccine comprising a mosaic protein
BR112017024283A8 (en) VACCINES AGAINST DENGUE
BR112017013270A2 (en) "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition."
BR112018072592A2 (en) yeast vaccine vector that includes immunostimulating and antigenic polypeptides, and methods of using them